Company Overview - Dunbo Medical, established in 2018, is headquartered in Xi'an, Shaanxi Province, focusing on the research and production of Class III active implantable medical devices [27] - The company has developed key medical and semiconductor technologies, including proprietary mixed-signal chips, hardware circuits, software applications, and structural materials [27] - Dunbo Medical has completed four rounds of financing to support its growth and innovation [27] Product Introduction - Dunbo's core product is a leadless cardiac pacemaker, which integrates the pulse generator and pacing electrode into a compact capsule that can be directly implanted into the heart [14][15] - The leadless pacemaker has advantages such as a smaller size (0.8cc), ease of use, and safety, eliminating complications associated with traditional lead-based systems [10][15] - The product's design allows for no visible skin incision or scarring, reducing the risk of infection and damage associated with lead wires [14][15] Market Overview - The prevalence of heart failure in China is increasing, with approximately 13.7 million patients aged 35 and older, and an annual increase of around 3 million new cases [16] - The cardiac pacemaker market in China is projected to reach 6.8 billion yuan in 2024, with imported products holding a market share of 89%, indicating a significant opportunity for domestic alternatives [16] - Despite the absence of successful domestic CRT products, there have been notable advancements in other innovative devices for heart failure treatment, such as left ventricular assist devices and cardiac contractility modulators [16][27] Innovations in Heart Failure Treatment - The left ventricular assist device (LVAD) market is maturing, with four domestic systems approved for market, each with unique advantages [17][18][20][22] - The D-shunt atrial shunt device has entered the "national innovative medical device" green channel, with plans for market approval in early 2024 [23][24] - The cardiac contractility modulator (CCM) developed by Lepu Medical has passed special review and is expected to receive approval soon [25]

Core Viewpoint - The Global Cardiovascular Conference 2025 highlighted the latest advancements in cardiovascular technology innovation, emphasizing the importance of clinical-driven and industry collaboration for the growth of the cardiovascular device sector [1][10][71]. Group 1: Conference Overview - The conference was held on May 15, 2025, in Beijing, gathering over 600 professionals from clinical, research, industry, and investment sectors to discuss cardiovascular technology innovation and enterprise growth paths [1]. - The event featured the release of the "2025 Global Cardiovascular Innovation Annual White Paper," which presented the latest development patterns in the cardiovascular device market [10]. Group 2: Awards and Recognition - The conference awarded three major prizes: the "2025 Global Cardiovascular Technology Innovation Award," the "2025 Global Cardiovascular Clinical Application Award," and the "2025 Global Cardiovascular International Cooperation Award," recognizing outstanding contributions in technology breakthroughs and clinical applications [13][14]. - A total of 10 companies received the technology innovation award, while 7 companies were recognized for clinical applications, and 4 units received the international cooperation award [13][14]. Group 3: Policy and Support - The Haidian District government expressed strong support for cardiovascular medical technology as a strategic direction, aiming to promote the market reach of cardiovascular devices [5]. - Beijing's policy support will focus on enhancing "clinical-driven + industry collaboration" mechanisms to facilitate innovation and results transformation in the cardiovascular field [7]. Group 4: Clinical and Engineering Collaboration - Experts emphasized the need for deep collaboration between clinical practitioners and engineers to address clinical pain points and drive innovation in cardiovascular devices [17][23]. - The conference featured discussions on the evolution of coronary intervention techniques and the importance of integrating clinical needs into device development [20][23]. Group 5: Investment Insights - The cardiovascular device sector is entering a critical window where companies with original technologies and systematic compliance capabilities will be highly valued by capital and policy [50]. - Early-stage companies face challenges in selecting the right market segments, while mid-stage companies must navigate structural adjustments and new payment logic to survive [51]. Group 6: Market Education and Product Strategy - The importance of educating the market on new surgical techniques and fostering collaboration between clinicians and engineers was highlighted as essential for successful product adoption [69]. - Companies are encouraged to build a product matrix that supports long-term growth and resilience against market fluctuations [63]. Group 7: Future Outlook - The conference served as a starting point for further discussions on how to leverage original technologies and promote Chinese innovations on the global stage [71][72]. - The cardiovascular industry is poised for transformation, driven by policy changes and technological advancements, necessitating a focus on clinical value and collaborative innovation [71].